Mereo BioPharma Group (MREO) Earnings Analysis

Mereo BioPharma Group (MREO) next reports earnings on 2026-08-11, consensus EPS -0.01 USD. Last quarter (2026-03-19) it beat with EPS -0.01 USD vs -0.01 USD est (0%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -1.33.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MREO next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.01 USD
Revenue estimate0.00B

MREO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.01 USD-0.01 USD0%Beat
2025-11-10-0.01 USD-0.00833 USD-20%Miss
2025-08-12-0.02 USD-0.01 USD-100%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

MREO valuation and analyst view

Trailing P/E-1.33
Trailing EPS-0.22261 USD
Price / book1.40
Dividend yield0.00%
Market cap0.05B
Analyst consensusBuy (5 buy / 3 hold / 0 sell)
Avg price target2.13 USD

Related research pages

Frequently asked questions

When is Mereo BioPharma Group (MREO)'s next earnings date?

Mereo BioPharma Group is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.01 USD and revenue estimate of 0.00B.

Did MREO beat earnings last quarter?

In its 2026-03-19 report, MREO posted EPS of -0.01 USD versus a -0.01 USD estimate — a beat of 0%.

What is MREO's earnings track record?

Over the last 3 reported quarters with consensus data, MREO beat estimates 1 times (33%).

What is MREO's current P/E ratio and EPS?

MREO trades at a trailing P/E of -1.33 on trailing EPS of -0.222614679516382 USD.

What do analysts rate MREO?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 2.13 USD.